D tier · weak
The famous 63% figure is a maximum, not a mean, from an unpublished supplier in-house study in 17 women over 28 days, and no peer-reviewed trial has ever tested acetyl octapeptide-3 as a single active - the only two published human studies containing it are multi-ingredient microneedle patches. ClinicalTrials.gov returns zero registered studies, and the "topical botox" framing rests on a SNARE-competition mechanism never demonstrated in human skin.
snap-8
SNAP-8 is an octapeptide corresponding to a fragment of SNAP-25, the SNARE protein required for acetylcholine vesicle fusion, acetylated at the N-terminus and amidated at the C-terminus. It carries the INCI name Acetyl Octapeptide-3 (also encountered as acetyl glutamyl heptapeptide-1) and was introduced by Lipotec as a topical alternative to botulinum toxin, extending the shorter and better-studied Argireline sequence by two residues. Its efficacy record consists of supplier in-house profilometry rather than peer-reviewed trials.
// we supply this one
available as a research reagent
≥ 98% HPLC · lyophilised powder · batch certificate published. Grade D above is our own and is not adjusted because we stock it.
the explanation
SNAP-8 is a lab-made copy of a small part of a protein that nerves use to release the signal telling muscles to contract. It is sold in creams as a needle-free alternative to Botox. The famous claim that it cuts wrinkle depth by 63% comes from the company that sells it, was the best single result rather than the average, and has never been published in a scientific journal or repeated by anyone independent.
regulatory status
Regulated cosmetic ingredient in the UK and EU; not a licensed medicine anywhere
Acetyl Octapeptide-3 is a listed INCI cosmetic ingredient with declared functions of humectant and skin conditioning, lawfully used in leave-on skincare in Great Britain under the retained UK cosmetics regime and in the EU and Northern Ireland under Regulation (EC) No 1223/2009, subject to a Cosmetic Product Safety Report and Product Information File. That clearance is for topical application to intact skin; the cosmetics framework excludes products intended for ingestion, inhalation, injection or implantation, and MHRA Guidance Note 8 weighs product form and claims together in deciding whether something is a medicinal product - a peptide marketed as a substitute for a prescription neurotoxin is close to that boundary. There is no MHRA, EMA or FDA approval of the peptide as a medicine. It is not named on the current WADA Prohibited List, but the S0 non-approved-substances clause would capture any substance without approval for human therapeutic use if presented for systemic use, and it has no documented status as a lawful dietary-supplement ingredient in the UK or US.
how it works · proposed mechanism
Botulinum toxin type A works intracellularly, cleaving SNAP-25 inside the presynaptic terminal of the motor neuron so that acetylcholine-containing vesicles cannot dock and fuse. SNAP-8 is a fragment of SNAP-25 itself, and the supplier's proposal is that it competes with the native protein for its place in the SNARE complex, blunting exocytosis. The whole claim therefore depends on a hydrophilic, multiply charged octapeptide reaching the inside of a nerve terminal beneath the dermis.
SNARE competition, as claimed by the supplier
Lipotec's product literature states that the peptide competes with the native protein for a position in the SNARE complex that is essential for muscle contraction, reducing neuronal excitability and so decreasing expression wrinkles. That is a mechanistic assertion in a commercial product sheet, not a published experiment. No electrophysiology, no vesicle-fusion assay and no immunohistochemistry in human skin is offered anywhere in the peer-reviewed literature for this specific peptide.
Relationship to Argireline: an extension, not an improvement
Acetyl hexapeptide-8 (Argireline, Ac-EEMQRR-NH2) covers the same SNAP-25 region and has multiple published anti-wrinkle studies; SNAP-8 simply adds Ala-Asp to the C-terminus. The reputation of the class is Argireline's, and SNAP-8's positioning as the better version rests on a supplier head-to-head comparison rather than on independent data. Notably, in the one independent randomised trial that tested acetylhexapeptide-3 topically, instrumental endpoints were non-significant.
The delivery problem the mechanism ignores
The peptide carries three acidic and two basic side chains and no lipid anchor, giving it a large polar surface and negligible partition into the stratum corneum. Acetylation and amidation improve resistance to amino- and carboxypeptidases but do nothing for permeation. Getting from the skin surface into the cytosol of a facial motor neuron requires crossing the stratum corneum, the epidermis, the dermis and a neuronal membrane - a sequence that has never been demonstrated for this molecule.
Why the microneedle studies do not rescue it
The only two peer-reviewed human studies containing acetyl octapeptide-3 delivered it through dissolving hyaluronic acid microneedle patches alongside other actives: ascorbyl glucoside and cyclic lysophosphatidic acid in a 24-subject study, and arginine/lysine polypeptide, palmitoyl tripeptide-5, adenosine and seaweed extracts in the other. Both bypass the stratum corneum mechanically and neither isolates the peptide's contribution. Their results cannot be attributed to SNAP-8 and say nothing about a cream.
what’s reported
evidence shape
7 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
The number that sells this peptide is not a trial result. Lipotec's product sheet describes an in-house study in 17 women over 28 days, with silicone imprints around the eyes analysed by confocal profilometry, and reports that the maximum reduction value of wrinkle depth was 63% - a best-case single measurement, not a mean, not placebo-controlled in any described way, and never published or peer-reviewed. A PubMed search for the exact term acetyl octapeptide-3 returns two records, both dissolving-microneedle patch studies in which the peptide is one of several actives delivered through a mechanically breached stratum corneum, so neither can attribute anything to SNAP-8. ClinicalTrials.gov returns zero registered studies. The peptide's reputation is largely inherited from the shorter Argireline sequence, which does have published trials - and in the one independent randomised topical trial of acetylhexapeptide-3, corneometry, TEWL and cutometry were all non-significant. Selling this compound as a lyophilised vial compounds the problem: even the weak evidence that exists is topical-only, and a charged octapeptide with no lipid anchor has no demonstrated route from anywhere to a motor nerve terminal.
key published findings
- Lipotec product literature (COSSMA product information): 17 women, 28 days, silicone imprints around the eyes analysed by confocal profilometry, maximum wrinkle-depth reduction reported as 63%; no peer-reviewed publication is cited anywhere in the document.
- PubMed contains exactly two records for the exact phrase acetyl octapeptide-3, and neither tests it alone.
- Shin 2024 (Ann Dermatol): dissolving microneedle patch containing acetyl octapeptide-3 with ascorbic acid 2-glucoside and sodium cyclic lysophosphatidic acid in 24 subjects over 28 days improved eye wrinkles and elasticity versus placebo - a multi-active patch, not a SNAP-8 cream.
- Avcil 2020 (J Cosmet Dermatol): hyaluronic acid microneedle patch loaded with arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts reduced fine lines by 25.8% and increased dermal density by 14.2%; the contribution of any single peptide is unrecoverable.
- Aruan 2023 (J Clin Aesthet Dermatol): in the closest independent randomised test of the shorter parent analogue, acetylhexapeptide-3 cream produced non-significant corneometer, tewameter and cutometer results (p>0.05) over 8 weeks in seven subjects per arm.
- ClinicalTrials.gov returns zero registered studies for SNAP-8, acetyl octapeptide or acetyl glutamyl heptapeptide.
limitations of the evidence
- The headline efficacy figure is a maximum rather than a mean, from a supplier document with no protocol, randomisation, blinding or statistics disclosed, and no peer review.
- No published study has tested acetyl octapeptide-3 as the only active variable, so no effect can be attributed to it.
- Both peer-reviewed studies containing it used microneedle patches that bypass the stratum corneum, which is precisely the barrier a cream must cross.
- The claimed SNARE-competition mechanism has never been demonstrated in human skin, and no human electrophysiological, neurophysiological or histological endpoint has been reported for the peptide.
- Argireline, the shorter analogue whose reputation SNAP-8 trades on, is a different molecule with its own trial record, and even that record is mixed - the one independent randomised topical test of acetylhexapeptide-3 was null on instrumental measures.
- Physicochemistry argues against the marketing: a multiply charged octapeptide with no lipidation has poor prospects of transdermal delivery to a presynaptic compartment, and no permeation study for this peptide has been published.
documented safety signals
- Topical tolerability appears good in the limited record: no adverse effects were reported over 28 days in the 24-subject microneedle patch study, and the patch study in the other publication reported excellent tolerability.
- As a listed INCI cosmetic ingredient it sits within the UK and EU cosmetics safety framework, which requires a qualified safety assessor's report for each finished topical product - a safety clearance for skin contact, not evidence of pharmacological safety.
- No irritation, sensitisation or systemic toxicity dataset specific to acetyl octapeptide-3 is publicly available in a regulatory safety assessment comparable to the CIR palmitoyl peptide reviews.
- There are no safety data of any kind for injection, ingestion or inhalation; absence of reported harm by those routes reflects absence of study, not evidence of safety, and the product is marketed with a neuromuscular mechanism claim that would be a medicinal claim if it were true.
identity
| full name | Acetyl octapeptide-3 (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2), an N-acetylated, C-amidated octapeptide fragment of SNAP-25 |
| category | Cosmetic |
| modality | peptide |
| formula | C41H70N16O16S |
| molar mass | 1075.2 g/mol |
| cas | 868844-74-0 |
| sequence | Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 |
laboratory handling
| storage | Lyophilised powder is stored desiccated at -20 °C and protected from light. Once reconstituted, laboratory practice is refrigeration at 2-8 °C for short-term use, or aliquoting and freezing to avoid repeated freeze-thaw cycles. Handling information only; this material has no approved human use. |
| solubility | Short hydrophilic peptide, readily soluble in sterile or bacteriostatic water and in dilute aqueous buffer. Lot-specific solubility is stated on the certificate of analysis. |
| co-studied with | Marketed almost exclusively in multi-peptide formulations, frequently with acetyl hexapeptide-8, palmitoyl peptides or hyaluronic acid, and in microneedle patches; because no study isolates it, none of those combination results can be read as evidence for this peptide. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
7 citedMedicines and Healthcare products Regulatory Agency · 2025 · official
Annals of Dermatology · 2024 · clinical study
Journal of Cosmetic Dermatology · 2020 · clinical study
Journal of Clinical and Aesthetic Dermatology · 2023 · randomized
PubChem, National Library of Medicine · 2026 · reference
Lipotec, published in COSSMA · 2010 · press release
COSMILE Europe · 2026 · tertiary
Sources marked tertiary or press release are the weakest citations on this page.
others in Cosmetic